Updates in CLL: Strategies for Managing Toxicities and Special Patient Considerations

Amy Goodrich, RN, MSN, CRNP, and Kirollos S. Hanna, PharmD, BCPS, BCOP, provide an overview of chronic lymphocytic leukemia (CLL) and the role BTK inhibitors play in treatment.

Two experts discuss their approach to selecting therapy for patients with CLL and provide insight on managing adverse events when using BTK inhibitors.

Amy Goodrich, RN, MSN, CRNP, and Kirollos S. Hanna, PharmD, BCPS, BCOP, answer audience questions regarding CLL and BTK inhibitors during a question & answer session.